KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) FCF Margin (2016 - 2026)

Bristol Myers Squibb has reported FCF Margin over the past 18 years, most recently at 6.59% for Q1 2026.

  • Quarterly FCF Margin fell 853.0% to 6.59% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 24.56% through Mar 2026, down 291.0% year-over-year, with the annual reading at 26.65% for FY2025, 221.0% down from the prior year.
  • FCF Margin was 6.59% for Q1 2026 at Bristol Myers Squibb, down from 12.83% in the prior quarter.
  • Over five years, FCF Margin peaked at 49.02% in Q3 2025 and troughed at 6.59% in Q1 2026.
  • The 5-year median for FCF Margin is 25.95% (2022), against an average of 26.16%.
  • The largest YoY upside for FCF Margin was 1207bps in 2025 against a maximum downside of -2007bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 25.95% in 2022, then surged by 32bps to 34.17% in 2023, then decreased by -4bps to 32.9% in 2024, then crashed by -61bps to 12.83% in 2025, then plummeted by -49bps to 6.59% in 2026.
  • Per Business Quant, the three most recent readings for BMY's FCF Margin are 6.59% (Q1 2026), 12.83% (Q4 2025), and 49.02% (Q3 2025).